Stroke prevention using the oral direct thrombin inhibitor ximelagatran inpatients with nonvalvular atrial fibrillation. Pooled analysis from the SPORTIF III ad V studies.

Hans-Christoph Diener, The Executive Steering Committee on behalf of the SPORTIFIII and V Investigators, Bertil Olsson

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Stroke prevention using the oral direct thrombin inhibitor ximelagatran inpatients with nonvalvular atrial fibrillation. Pooled analysis from the SPORTIF III ad V studies.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science